Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03106571 · ClinicalTrials.gov registry record · Phase 1
Study of Pomaglumetad and Methamphetamine
A Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03106571: Clinical Trial Phase 1 study, sponsored by University of California, Los Angeles.
NCT03106571 is a Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03106571, a Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is the first study of pomaglumetad in humans using methamphetamine. The goal of the study is to determine if pomaglumetad is safe when administered with methamphetamine. If shown to be safe with methamphetamine in the current study, a phase 2 clinical trial of pomaglumetad would be done to begin to find out if pomaglumetad is effective in treating methamphetamine use disorder.
Primary Outcome
Blood pressure following IV methamphetamine during treatment with pomaglumetad or placebo
Interventions
- DRUG Placebo
- DRUG Methamphetamine
- DRUG Pomaglumetad methionil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 1 |
Why NCT03106571 stopped before completion
NCT03106571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03106571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03106571 about?
NCT03106571 is a clinical study titled "Study of Pomaglumetad and Methamphetamine". This is the first study of pomaglumetad in humans using methamphetamine. The goal of the study is to determine if pomaglumetad is safe when administered with methamphetamine. If shown to be safe with methamphetamine in the current study, a phase 2 clinical trial of pomaglumetad would be done to begi...
What is the current status of trial NCT03106571?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2017-08-01. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03106571?
The interventions under investigation include: Placebo (DRUG), Methamphetamine (DRUG), Pomaglumetad methionil (DRUG).
Who is sponsoring clinical trial NCT03106571?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03106571's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI